Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02728388 · ClinicalTrials.gov registry record · Phase 2
Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II
A Phase 2 study of Neurofibromatosis 1, sponsored by Donald Basel.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02728388: Recruiting Phase 2 study of Neurofibromatosis 1, sponsored by Donald Basel.
NCT02728388 is a Phase 2 study of Neurofibromatosis 1 that is actively recruiting participants, run by Donald Basel. The registered enrollment target is 30 participants, below the 1,034-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02728388, a Phase 2 study of Neurofibromatosis 1, is actively recruiting participants, sponsored by Donald Basel.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators wish to determine the time to disease progression for benign neurofibromas treated with Levulan Kerastick topical photosensitizer and red light photodynamic therapy (PDT) in patients with neurofibromatosis type 1 (NF1). The investigators also wish to measure tumor size for control and treatment tumors in order to gain insights into tumor growth rates.
Primary Outcome
The time it takes for 50% growth in tumor size over baseline measurements.
Conditions Studied
Interventions
- DRUG aminolevulinic acid
Study Locations (1)
Wisconsin
- Donald G Basel - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-08 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
What NCT02728388 shows while recruiting
NCT02728388 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,034-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Neurofibromatosis 1 appearing as the primary indexed condition, and to 1 intervention - of which aminolevulinic acid is the first listed.
NCT02728388 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT02728388 about?
NCT02728388 is a clinical study titled "Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II". The investigators wish to determine the time to disease progression for benign neurofibromas treated with Levulan Kerastick topical photosensitizer and red light photodynamic therapy (PDT) in patients with neurofibromatosis type 1 (NF1). The investigators also wish to measure tumor size for control...
What is the current status of trial NCT02728388?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2016-08. Estimated completion is 2025-12.
What conditions does trial NCT02728388 study?
This clinical trial studies the following conditions: Neurofibromatosis 1.
What interventions are being tested in trial NCT02728388?
The interventions under investigation include: aminolevulinic acid (DRUG).
Who is sponsoring clinical trial NCT02728388?
This trial is sponsored by Donald Basel, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02728388 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02728388's enrollment target sits among peer trials
30 20th of 24 higher than 4 of 24 other Neurofibromatosis 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neurofibromatosis 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
RECRUITING · Phase 2
-
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1
ACTIVE NOT RECRUITING · Phase 2
-
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
COMPLETED · Phase 2
-
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
RECRUITING · NA
-
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
RECRUITING · NA
-
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia